Published by MyelinWatch:
ReWRAP · ReWRAP tested bazedoxifene as a possible way to affect cells involved in myelin repair. The Phase 2 study has finished.
ReWRAP tested bazedoxifene as a possible way to affect cells involved in myelin repair. The Phase 2 study has finished.
Phase 2 study in people
The study's main and secondary measures of myelin repair were not reached
The study did not meet its primary or secondary myelin-repair measures and found no clear benefit on those measures. It was generally well tolerated; the result does not establish benefit.
ReWRAP did not show the hoped-for effect on its planned measures. It is not an available treatment for myelin repair.
In ReWRAP, bazedoxifene was generally well tolerated. However, it did not show a clear improvement in either the main MRI measure of myelin or the study's other measures of whether the treatment worked.
Source: ClinicalTrials.gov / ACTRIMS 2026 — official ClinicalTrials.gov record ↗
